• Je něco špatně v tomto záznamu ?

Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party

N. Santoro, JE. Mooyaart, R. Devillier, Y. Koc, J. Vydra, L. Castagna, Z. Gülbas, JD. Martin, MC. Araujo, A. Kulagin, M. Arat, CH. Arroyo, MP. Martelli, M. Di Ianni, JD. Hoogenboom, LC. de Wreede, A. Ruggeri, C. Chabannon

. 2023 ; 58 (1) : 54-60. [pub] 20221010

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004802
E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 1 rokem
Freely Accessible Science Journals od 1997 do Před 1 rokem
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 36216975
DOI 10.1038/s41409-022-01839-8
Knihovny.cz E-zdroje

Donor lymphocyte infusion (DLI) is a treatment option to prevent or treat relapse after allogeneic hematopoietic cell transplantation (HCT). We here report data for 173 patients who received one or multiple DLIs after haploidentical-HCT with post-transplant cyclophosphamide (PTCY) at 47 EBMT centers from 2009 to 2018. Indication for DLI was: prophylactic for 59 (34.3%), preemptive for 20(11.6%), and therapeutic for 93(54.1%). For the prophylactic group, the median number of DLIs was 1 (IQR:1-2.5) with a median first dose of 0.1 × 106 CD3+ T cell/kg, for the preemptive 2 (IQR:1-3) with 0.5 × 106 CD3+ T cell/kg, for the therapeutic 1 (IQR:1-3) with 1 × 106CD3+ Tcell/kg, respectively. OS after first DLI was 61% (46-75%) for prophylactic, 40% (19-61%) for preemptive, and 22% (13-31%) for therapeutic. CI of II-IV aGVHD and cGVHD was 17% (7-27%) and 53% (40-67%) for the prophylactic, 20% (2-38%) and 21% (3-39%) for the preemptive, 17% (9-24%) and 24% (15-33%) for the therapeutic group, respectively. Our data show great variability in the indications and modalities of DLI across responding EBMT centers. Survival rates remain relatively low in patients with active disease. While the cumulative incidence of aGVHD appears acceptable, we showed a high incidence of cGVHD in the prophylactic group, compared with preemptive and therapeutic DLI. These data should be investigated further in prospective clinical trials.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004802
003      
CZ-PrNML
005      
20230425171729.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41409-022-01839-8 $2 doi
035    __
$a (PubMed)36216975
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Santoro, Nicole $u Department of Hematology and Oncology, Ospedale Civile "Santo Spirito", Pescara, Italy. nicole.santoro24@gmail.com $1 https://orcid.org/0000000157058084
245    10
$a Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party / $c N. Santoro, JE. Mooyaart, R. Devillier, Y. Koc, J. Vydra, L. Castagna, Z. Gülbas, JD. Martin, MC. Araujo, A. Kulagin, M. Arat, CH. Arroyo, MP. Martelli, M. Di Ianni, JD. Hoogenboom, LC. de Wreede, A. Ruggeri, C. Chabannon
520    9_
$a Donor lymphocyte infusion (DLI) is a treatment option to prevent or treat relapse after allogeneic hematopoietic cell transplantation (HCT). We here report data for 173 patients who received one or multiple DLIs after haploidentical-HCT with post-transplant cyclophosphamide (PTCY) at 47 EBMT centers from 2009 to 2018. Indication for DLI was: prophylactic for 59 (34.3%), preemptive for 20(11.6%), and therapeutic for 93(54.1%). For the prophylactic group, the median number of DLIs was 1 (IQR:1-2.5) with a median first dose of 0.1 × 106 CD3+ T cell/kg, for the preemptive 2 (IQR:1-3) with 0.5 × 106 CD3+ T cell/kg, for the therapeutic 1 (IQR:1-3) with 1 × 106CD3+ Tcell/kg, respectively. OS after first DLI was 61% (46-75%) for prophylactic, 40% (19-61%) for preemptive, and 22% (13-31%) for therapeutic. CI of II-IV aGVHD and cGVHD was 17% (7-27%) and 53% (40-67%) for the prophylactic, 20% (2-38%) and 21% (3-39%) for the preemptive, 17% (9-24%) and 24% (15-33%) for the therapeutic group, respectively. Our data show great variability in the indications and modalities of DLI across responding EBMT centers. Survival rates remain relatively low in patients with active disease. While the cumulative incidence of aGVHD appears acceptable, we showed a high incidence of cGVHD in the prophylactic group, compared with preemptive and therapeutic DLI. These data should be investigated further in prospective clinical trials.
650    _2
$a lidé $7 D006801
650    _2
$a prospektivní studie $7 D011446
650    12
$a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
650    _2
$a cyklofosfamid $x terapeutické užití $7 D003520
650    _2
$a imunoterapie adoptivní $x škodlivé účinky $7 D016219
650    _2
$a transfuze lymfocytů $x škodlivé účinky $7 D017710
650    _2
$a lymfocyty $7 D008214
650    12
$a nemoc štěpu proti hostiteli $x etiologie $7 D006086
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mooyaart, Jarl E $u EBMT Statistical Unit, Leiden, The Netherlands
700    1_
$a Devillier, Raynier $u Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer, & Centre de Recherches en Cancérologie de Marseille (CRCM), Inserm UMR 1068, Université d'Aix-Marseille, Marseille, France $1 https://orcid.org/0000000240458310
700    1_
$a Koc, Yener $u Medicana International Hospital Istanbul, Istanbul, Turkey
700    1_
$a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000242743895
700    1_
$a Castagna, Luca $u Istituto Clinico Humanitas, Milano, Italy
700    1_
$a Gülbas, Zafer $u Anadolu Medical Center Hospital, Kocaeli, Turkey
700    1_
$a Martin, José Diez $u Servicio de Hematología Hospital G. Universitario Gregorio Marañon, Instituto de Investigación sanitaria Gregorio Marañon, Department of Medicine Universidad Complutense, Madrid, Spain
700    1_
$a Araujo, Mercedes Colorado $u Hospital U. Marqués de Valdecilla, Santander, Spain
700    1_
$a Kulagin, Alexander $u RM Gorbacheva Research Institute, Pavlov University, St, Petersburg, Russia $1 https://orcid.org/0000000295894136
700    1_
$a Arat, Mutlu $u Demiroglu Bilim University Istanbul Florence Nightingale Hospital Istanbul, Istanbul, Turkey $1 https://orcid.org/0000000320398557
700    1_
$a Arroyo, Concepcion Herrera $u Hospital Universitario Reina Sofia. IMIBIC. University of Cordoba, Cordoba, Spain $1 https://orcid.org/0000000300552270
700    1_
$a Martelli, Maria Paola $u Institute of Hematology, Centro Ricerche Emato-Oncologiche, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy
700    1_
$a Di Ianni, Mauro $u Department of Hematology and Oncology, Ospedale Civile "Santo Spirito", Pescara, Italy $1 https://orcid.org/0000000267014023
700    1_
$a Hoogenboom, Jorinde D $u EBMT Leiden Study Unit, Leiden, The Netherlands
700    1_
$a de Wreede, Liesbeth C $u Leiden University Medical Center, Leiden, The Netherlands $1 https://orcid.org/0000000276679369
700    1_
$a Ruggeri, Annalisa $u San Raffaele Scientific Institute, Hematology and Bone marrow Transplantation unit, Milan, Italy $1 https://orcid.org/0000000272612765
700    1_
$a Chabannon, Christian $u Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer & Centre d'Investigations Cliniques en Biothérapie, Université d'Aix-Marseille, Inserm CBT, 1409, Marseille, France $1 https://orcid.org/0000000237554889
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 58, č. 1 (2023), s. 54-60
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36216975 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171725 $b ABA008
999    __
$a ok $b bmc $g 1925098 $s 1191011
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 58 $c 1 $d 54-60 $e 20221010 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace